Arriva raises $6M for respiratory work

Alameda, CA-based Arriva Pharmaceuticals has rounded up $6 million in funding to advance its work on anti-inflammatory therapies for treating respiratory disease. The round was led by Nordic Biotech; MPM BioVentures also participated. CEO Sue Preston said the funding will be used to develop the company's recombinant
alpha-one antitrypsin for hereditary emphysema.

- see this release

PLUS: With help from Domain Associates, San Diego's Obalon Therapeutics has secured $4.7 million of a 7.7 million first round. Item

Related Articles:
Biotech, emerging markets are big VC targets. Report
Serial investors: Comforting figures for VC backers. Report
VC adds billions in its pursuit of biotech ventures. Report

Suggested Articles

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.

Lilly has created customized mobile research units to run the clinical trial as the long-term care facilities lack experience running studies.